Exercise of Options and Total Voting Rights

RNS Number : 6913B
Omega Diagnostics Group PLC
09 October 2020
 

 

OMEGA DIAGNOSTICS GROUP PLC

 

("Omega" or the "Company" or the "Group")

 

Exercise of Options and Total Voting Rights

 

9 October 2020

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 38,043 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options by an ex-employee.

Application has been made to the London Stock Exchange for the 38,043 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 15 October 2020.

 

After Admission, the total number of Ordinary Shares in issue will be 178,716,153 and the total number of voting rights will therefore be 178,716,153 . This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

 

Contacts: 

 

Omega Diagnostics Group PLC 

Tel: 01259 763 030

Colin King, Chief Executive 

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director






finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance)


Alice Lane (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRFSIFIUESSESS
UK 100

Latest directors dealings